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Abstract
Background: The lymphatic vessels play a crucial role in a variety of human cancers since tumour
cell lymphatic invasion significantly influences prognosis. It is not known if pre-existing lymphatics
are enough for tumour dissemination or de novo development is necessary. VEGFR-3 is an
angiogenetic mediator for both lymphatic and blood vessels during embryonic development, and
only for lymphatics after birth. VEGF is a mediator of both vasculogenesis and angiogenesis,
regulates the growth of lymphatics in various experimental models, and is produced in many solid
tumours. CD44 mediates hyaluronic acid (HA)-dependent cell adhesion: besides promoting
invasion, this interaction also supports neoangiogenesis that indirectly stimulates tumour cell
proliferation. The expression of VEGF-C (Vascular Endothelial Growth Factor – C), its receptor
VEGFR-3 and CD44, were studied on feline mammary samples to assess the importance of
lymphangiogenesis and lymphangiotrophism in neoplasia.
Methods: Samples were taken from six normal mammary glands (NMG), ten benign (BT) and 32
malignant (MT) tumours. Immunohistochemical laminin/VEGFR-3 double stain, VEGF-C and CD44
stains were applied to 4 μm-thick sections, and their expression evaluated in intratumoral/
extratumoral and intramammary/extramammary fields.
Results: All groups revealed a higher number of lymphatics in the extratumoral/extramammary
areas. VEGF-C expression in the epithelium paralleled the number of positive vessels in the NMG,
BT and MT, whereas VEGF-C higher expression was noted in the intratumoral fields only in
infiltrating MT. CD44 score was lower in extratumoral than intratumoral fields in tumours and
showed a significant increase in extramammary/extratumoral fields from NMG to MT. Pearson test
showed a significant and inversely proportional correlation between CD44 expression and the
number of lymphatic vessels with VEGFR-3 in malignant infiltrating tumours.
Conclusion: The number of both VEGFR-3 positive and negative lymphatics in the extratumoral
and extramammary stroma was significantly higher than intratumoral and intramammary fields
respectively in the NMG, BT and MT. This suggests a scant biological importance of intratumoral
lymphatics while their higher number is due to the concentration of existing vessels following
compression of the extratumoral stroma in spite of a non demonstrable increase from NMG to
MT. The tumour model employed provided no evidence of lymphangiogenesis, and metastasis in
the regional lymph node develops following the spread through the pre-existing lymphatic network.
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Background
The lymphatic vessels play a crucial role in a variety of
human cancers since tumour cell lymphatic invasion and
subsequent development of lymph node metastases sig-
nificantly influences prognosis. Therefore the lymphatic
pathway is an integral part of tumour staging [1].
It is well established that for many carcinomas transport
of tumour cells via the lymphatics is the most common
pattern of initial dissemination. However, it is not known
if pre-existing lymphatics are enough for tumour dissemi-
nation or de novo development is necessary [2].
Until recent years, the lack of specific markers has raised
problems in documenting exactly how the lymphatic sys-
tem develops. The markers recently identified are the
homeobox gene Prox-1, involved in the early phases of
lymphatic vessel development [3]; Podoplanin, a 43 kDa
mucoprotein found on the membrane of glomerular
podocytes [4]; LYVE-1 (Lymphatic vessel endothelial
hyaluronan receptor-1), a lymphatic endothelial receptor
for hyaluronan, the extracellular matrix/lymphatic fluid
glycosaminoglycan [5].
These markers seemed to have solved the problem of
detecting the lymphatic vessels and, above all, their histo-
logical distinction from blood vessels. However, these
molecules are not always detectable in animal tissues, and
need to be used with specific blood vessel markers to dis-
criminate between the two vessel types. Many studies
highlighted the limits of these markers: i.e. LYVE-1 is
present not only in lymphatic vessels, but also in the
hepatic blood sinusoids [6], with a variable behaviour
according to the tumour type [5]. Podoplanin is not
highly specific, since it is also expressed by glomerular
podocytes. Prox-1 has an important role in the embryonic
development of lymphatic vessels [3], but is not clearly
expressed in lymphatics after birth or in adults [7].
The role of VEGFR-3 (Vascular Endothelial Growth Factor
Receptor-3) as an angiogenetic mediator was demon-
strated for both lymphatic and blood vessels during
embryonic development, and only for lymphatics (lym-
phangiogenesis) after birth [8]. VEGFR-3 is the receptor
for VEGF-C, and belongs to the vascular endothelial
growth factor (VEGF) protein family. VEGF, discovered in
1989, is a major mediator of both vasculogenesis and ang-
iogenesis. VEGF-C regulates the growth of lymphatics in
various experimental models [9], and is produced in
many solid tumours [10]. Its level of expression has been
suggested to correlate with angiogenesis and metastasis
via the lymphatic system [11].
CD44 is a broadly distributed transmembrane glycopro-
tein playing a critical role in a variety of cellular behav-
iours, including adhesion, migration, invasion, and
survival [12]. CD44 mediates hyaluronic acid (HA)-
dependent cell adhesion [13]: besides promoting inva-
sion, this interaction also supports neoangiogenesis that
indirectly stimulates tumour cell proliferation [14].
Our investigation employed an animal model known to
use the lymphatic pathway to metastasize, i.e. feline mam-
mary carcinoma, to assess the importance of lymphangio-
genesis as a step in this tumour model for the spread of
neoplastic cells through the lymphatics instead of blood
vessels.
Methods
Cases
The samples used originated from 48 cases: six normal
mammary glands, ten benign tumours (tubulo-papillary
adenoma) and 32 malignant (six in situ carcinomas, 12
tubulo-papillary carcinomas and 14 solid carcinomas) of
the mammary gland of female cats. Ethical approval for
the study was not required because cases were selected
among those routinely collected at the laboratory of his-
topathology for diagnostic purposes after mastectomy.
Each specimen had been formalin-fixed and paraffin-wax
embedded and histological diagnoses were performed on
Haematoxylin-Eosin stained sections according to the
WHO criteria by Misdorp et al. [15]. Malignancies were
then graded according to the histological staging method
developed by Gilbertson et al. [16] in the dog and adapted
to the cat by Mandelli et al. [17] as follows: stage 0 (St0)
or malignant non-infiltrating tumour, when the neoplas-
tic proliferation was limited by the basement membrane
(all these cases belong to the in situ carcinomas of the
WHO [15] classification); stage I (StI) or infiltrating
malignant tumour with stromal invasion (i.e. the tumour
proliferated beyond the basement membrane and
invaded the surrounding stroma); stage II (StII) or infil-
trating malignant tumour with lymphatic or blood
emboli and/or regional lymph node metastases. On the
basis of this gradation system, 6 malignancies resulted
stage 0 (in situ), 14 stage I and 12 stage II.
Immunohistochemistry
Four μm-thick sections from all the samples were immu-
nohistochemically stained with a laminin/VEGFR-3 dou-
ble stain, VEGF-C and CD44 stains.
Laminin/VEGFR-3 double stain reaction
Sections of formalin-fixed and paraffin-embedded sam-
ples were dewaxed and rehydrated. Antigen was
unmasked with 0.05% Pronase E (1.07433, Merck, Darm-
stadt, Germany) in Tris buffer pH 7.4 for 10 min at room
temperature followed by citrate buffer (2.1 g citric acid
monohydrate/liter distilled water) pH 6.0 in a microwaveBMC Cancer 2007, 7:7 http://www.biomedcentral.com/1471-2407/7/7
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oven at 750 W (two cycles of 5 min each); then the sec-
tions were allowed to cool at room temperature for 20
min. The first immunohistochemical step was the block of
peroxidase reagent with DAKO EnVision™ Doublestain
System (Dako, Amsterdam, The Netherlands) for 5 min
followed by primary polyclonal rabbit anti-mouse lam-
inin antibody (Sigma, St. Louis, Missouri, USA), diluted
1:200 in PBS containing 1% bovine serum albumin
applied overnight at 4°C. After a wash with TRIS buffer
the peroxidase labelled components (diaminobenzidine
as chromogen) of the DAKO EnVision™ Doublestain Sys-
tem were used to reveal this part of the double immuno-
histochemical stain. After a step with double staining
block solution of the DAKO EnVision™ Doublestain Sys-
tem, the primary polyclonal rabbit anti-mouse FLT-4/
VEGFR-3 antibody (Alpha Diagnostic International, San
Antonio, Texas, USA) diluted 1:350 in PBS containing 1%
of bovine serum albumin was applied for 60 min at room
temperature. After a wash with TRIS buffer the alkaline
phosphatase labelled components (fast red as chro-
mogen) of the DAKO EnVision™ Doublestain System
were used to reveal this second part of the double immu-
nohistochemical stain. Apart from primary antibodies, all
other steps were conducted following the kit manufac-
turer's instructions. Sections were counterstained with
Mayer's hematoxylin and mounted with DAKO Glycergel
Mounting Medium (Dako, Amsterdam, The Nether-
lands). Negative controls were achieved by incubating the
slides with a non-specific antibody of the same isotype. As
positive controls to assess the cross-reactivity with feline
tissues and the specificity of the immunohistochemical
stain of the anti-VEGFR-3 antibody a section of feline
intestine was used with the same protocol, employing one
of the two immunohistochemical DAKO EnVision™ Dou-
blestain System steps. The specificity and cross-reactivity
of the anti-laminin stain were evaluated as expected in
basement membranes surrounding glandular structures of
NMG, BT and MT, and around blood containing vessels.
VEGF-C and CD44 stains
Four μm-thick sections were dewaxed in toluene and rehy-
drated. Endogenous peroxidase was blocked by immer-
sion in 0.3% hydrogen peroxide for 20 min. Sections were
then rinsed in Tris Buffer and antigen retrieval was
obtained only for anti-CD44 stain with citrate buffer (2.1
g citric acid monohydrate/liter distilled water), pH 6.0,
and heating for two 5-min periods in a microwave oven at
750 W, followed by cooling at room temperature for 20
min. Sections were then preincubated with serum free
protein block (Dako, Amsterdam, The Netherlands) for
10 min at room temperature. The primary antibodies anti-
VEGF-C, clone Z-CVC7, diluted 1:12.5 (Zymed laborato-
ries inc., San Francisco, California, USA) and anti-
CD44var (v5), clone VFF-8, diluted 1:12.5 (Bender
MedSystems, Vienna, Austria) were applied overnight at
4°C and were followed by a commercial streptoavidin-
biotin-peroxidase technique (LSAB Kit, Dako, Amster-
dam, The Netherlands). Diaminobenzidine (0.05% for 10
min at room temperature) was used as chromogen. Slides
were counterstained with Papanicolaou's hematoxylin.
Negative controls were obtained substituting the primary
antibody with an unrelated monoclonal antibody of the
same isotype. As positive controls to assess the cross-reac-
tivity with feline tissues and the specificity of the immu-
nohistochemical stain of the anti-VEGF-C and anti-CD44
antibodies, a section of granulation tissue from a feline
healing skin lesion and one from a feline anaplastic mam-
mary carcinoma respectively were used following the
same protocols.
Scoring methods
Immunohistochemical expression was evaluated in intra-
tumoral (fields randomly chosen between lobules inside
the tumour) and extratumoral areas (between the external
border of the neoplasm and the subcutis or the muscle/
stromal plan of the abdomen or thorax). Intramammary
and extramammary fields were selected in the normal
mammary gland considering any area containing normal
lobuli and/or interlobular connective tissue in the first
case, and the subcutis or the muscle/stroma plan of the
abdomen or thorax in the second.
Lymphatic vessels expressing and not expressing VEGFR-3
were counted in ten intratumoral/intramammary fields
and 20 extratumoral/extramammary fields. Each field had
an area of 0.789 square mm and the microscope objective
used was 20x. Counts are expressed as the number of lym-
phatic vessels in ten square millimitres.
VEGF-C and CD44 immunohistochemical expressions
were analyzed with a 40x objective (corresponding to
0.196 mm2) on five intratumoral (intramammary) and
ten extratumoral (extramammary) fields, selecting the
areas with major expression (Hot Spots) at low magnifica-
tion. In each immunostained area, VEGF-C and CD44
were expressed as score index of the epithelial, adenoma-
tous and carcinomatous components as follows: absent =
0, i.e. no positive cells per field; low = 10, up to ten posi-
tive cells per field; intermediate = 100, fewer than 50%
positive cells per field; high = 1000, more than 50% posi-
tive cells per field. Only for VEGF-C were the number of
positive vessels in the same field also counted.
Statistical analysis
The variables (number of lymphatics expressing and not
expressing VEGFR-3, VEGF-C and CD44 scores, and
number of VEGF-C expressing vessels) were tested for nor-
mality with Shapiro Wilk's W Test and the data did not
show a normal distribution. Comparison between cases
grouped as for diagnosis (normal mammary gland,BMC Cancer 2007, 7:7 http://www.biomedcentral.com/1471-2407/7/7
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benign and malignant tumours), site of evaluation (intra-
tumoral/intramammary, extratumoral/extramammary)
and stage of invasion (non infiltrating, locally invasive
(StI) and with intravascular emboli (StII)) were evaluated
with the Spearman rank test. Pearson's correlation test was
employed to examine the variables relationship. Analyses
were performed by CSS software (Statsoft, Tulsa, OK,
USA) statistics, and a conventional 5% level was used to
define statistical significance.
Results
Immunohistochemical anti-laminin/anti-VEGFR3 double 
stain
Laminin in the basement membrane stained brown
(depending on the chromogen used), and VEGFR-3
intense red (figure 1). Laminin stain was also visible in the
sub-endothelial space of blood containing vessels around
alveoli and ducts in NMG and around tubules and papil-
lae in BT and most MT. VEGFR-3 in controls was revealed
as a granular cytoplasmic stain in some endothelial cells
of the lacteals and in some blood containing and non-
blood containing vessels of the intestinal wall. Lymphatic
vessels were recognized when laminin stain was unappre-
ciable (absence of the basement membrane), associated
or not with VEGFR-3 in the cytoplasm of the lining
endothelium. Blood capillaries were recognized when
continuous positive laminin stain was present, associated
or not with positive VEGFR-3 red staining in the cyto-
plasm of the lining endothelium. This study reports only
the results of lymphatics quantification. VEGFR-3 expres-
sion stained positive both in the blood and lymphatic
endothelium, in the epithelium of normal mammary
gland and in benign and malignant tumours.
Descriptive statistical data of the number of lymphatics
with or without VEGFR-3 expression in the groups com-
pared are reported in table 1. The number of total lym-
phatic vessels (i.e. those expressing and non expressing
VEGFR-3) was significantly higher in the extratumoral/
extramammary than intratumoral/intramammary areas
(Spearman test: P < 0.01 for NMG and MT; P < 0.05 for
BT). Both numbers of lymphatics with or without VEGFR-
3 expression in NMG and carcinomas had higher signifi-
cant values in extramammary/extratumoral fields com-
pared to intramammary/intratumoral stroma (Spearman
test; NMG: P < 0.05 for lymph vessels without and P <
0.01 for those with VEGFR-3 expression; MT: P < 0.05 for
lymph vessels without, and P < 0.01 for those with
VEGFR-3 expression), whereas in adenoma the same
result was obtained for lymphatic vessels with VEGFR-3
(Spearman test: P < 0.01). No significant difference was
disclosed in the number of lymphatics without VEGFR-3
expression (figure 2). A significantly higher number of
lymphatics without VEGFR-3 expression from NMGs to
MTs (Spearman test: P < 0.05) in the extratumoral
(extramammary) fields, but no significant difference in
the intratumoral (intramammary) fields was found in the
three diagnostic groups (normal mammary gland, benign
and malignant tumours). Grouping malignant tumours
according to stage, no significant difference was found in
the extratumoral stroma, and a significant increase in the
number of lymphatics expressing VEGFR-3 in the intratu-
moral stroma from stage 0 and I vs stage II (median val-
ues: stage 0 = 0.7; stage I = 0.8; stage II = 3.3; Spearman
test: P < 0.05) (figure 3).
Immunohistochemical anti-VEGF-C stain
Vascular endothelium and stromal fibroblasts in positive
controls and also the epithelium of both NMG, BT and
MT, in mammary samples showed a brown stain, strong
in the cytoplasm and light in the nucleus (figure 4).
Stained cells were located in "hot spots" in both benign
and malignant neoplasms.
Descriptive statistical data of the VEGF-C score index in
the comparison between groups are reported in table 2. A
significant association was found between VEGF-C expres-
sion in the epithelium and the number of positive vessels
(Pearson correlation, R = 0.67, P < 0.01) both in the nor-
mal mammary gland, and benign and malignant
tumours. In the malignant tumours (Spearman: P =
0.024), but not in the benign lesions (Spearman: P =
0.46) or in the normal mammary gland (Spearman: P =
0.62), the VEGF-C score index had higher and significant
values in the intratumoral (intramammary) than in extra-
Cat Figure 1
Cat. Mammary gland. VEGFR-3 (red) and laminin (brown) 
double immunohistochemical stain in an extratumoral area of 
a stage 0 carcinoma. Lymphatic vessels are laminin negative 
(asterisk) whereas blood vessels are laminin positive (circle) 
20X. Inset: higher magnification of VEGFR-3 positive 
endothelial cells in a lymphatic vessel. 63X.BMC Cancer 2007, 7:7 http://www.biomedcentral.com/1471-2407/7/7
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tumoral (extramammary) fields (figure 5). Comparing the
expression of VEGF-C of the epithelial component
between malignant infiltrating (St I+II) and non-infiltrat-
ing tumours (St0), a higher significant difference was
noted in the intratumoral than extratumoral fields in infil-
trating tumours (Spearman: P = 0.036), but not in non-
infiltrating neoplasms (Spearman: P = 0.31) (figure 5).
No relationship was found between the VEGF-C score in
epithelial cells and the diagnostic group (normal mam-
mary gland, benign and malignant tumours) or histologic
stage (0, I, II).
Immunohistochemical anti-CD44 stain
CD44 was immunohistochemically disclosed as a brown
cytoplasmic stain in the positive control (feline anaplastic
mammary carcinoma cells) and in the epithelium of
NMG as well as BT and MT (figure 6). The immunostain-
ing was concentrated in "hot spots" where the quantita-
tive analysis was focused both for normal mammary
gland and benign and malignant growths.
Descriptive statistical data of the CD44 score in the groups
compared are reported in table 3.
CD44 score was significantly lower in extratumoral than
intratumoral fields in both benign and malignant
tumours (Spearman: P < 0.01). The normal mammary
gland showed values close to significance (Spearman: P =
0.056). The comparison of intramammary/intratumoral
and extramammary/extratumoral fields showed a signifi-
cant increase in CD44 score in extramammary/extratu-
moral fields from NMG to MT (Spearman: P < 0.05)
(figure 7) but not in intramammary/intratumoral stroma.
The CD44 index was not correlated with stage progression
in MT.
Correlations of lymphatic assessment with VEGF-C and 
CD44 indices
The expression of VEGF-C and CD44 in the epithelial neo-
plastic cells was compared with the number of lymphatic
vessels with or without VEGFR-3 expression. Pearson test
showed a significant and inversely proportional correla-
Number of lymphatics with and without VEGFR-3 expression in intramammary/intratumoral (A, B) and extramammary/extra- tumoral (C, D) fields in normal mammary gland (NMG), benign tumours (BT) and malignant tumours (MT) Figure 2
Number of lymphatics with and without VEGFR-3 expression in intramammary/intratumoral (A, B) and extramammary/extra-
tumoral (C, D) fields in normal mammary gland (NMG), benign tumours (BT) and malignant tumours (MT).BMC Cancer 2007, 7:7 http://www.biomedcentral.com/1471-2407/7/7
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tion between CD44 expression and the number of lym-
phatic vessels with receptor in malignant infiltrating
tumours (StI + II) (R = -0.36; P = 0.18), but not in non-
infiltrating malignant tumours, benign tumours and nor-
mal mammary gland.
Discussion
On the basis of the results obtained, the distribution of
the lymphatic vessels produced quantitative data in the
intratumoral and extratumoral stroma of benign and
malignant tumours similar to those of the intra- and
extramammary areas of the normal mammary gland. In
all groups (normal mammary gland, benign tumours and
malignant tumours) the number of both VEGFR-3 posi-
tive and negative lymphatics in the extratumoral
(extramammary) stroma was significantly higher than
that in the intratumoral (intramammary) stroma.
These data emphasize in the cat, as in the human, there
are only a few lymphatic vessels in the intratumoral
stroma. This suggests a scant biological importance of the
intratumoral lymphatics that do not seem to be invaded
by neoplastic cells because of the high interstitial pressure
inside the tumour. The lymphatics are instead better rep-
resented in the extratumoral tissue where, as in the
woman, the mechanical stress is less intense, and presum-
ably due to the compression of the stroma in these areas
of concentration of the pre-existing vessels.
Like the extratumoral and intratumoral environment of
benign and malignant tumours, the lymphatics expressing
VEGFR-3 in the extramammary tissue of normal mam-
mary gland are about threefold those in the intramam-
mary stroma. The results of the normal mammary gland
and intra/extratumoral tissue obtained in this study sug-
gest that a new production of lymphatic vessels or lym-
phangiogenesis is extremely limited. No significant
increase in the number of lymphatic vessels expressing
VEGFR-3 was detected in extratumoral tissue. The lack of
an increase in lymphatic vessels demonstrated at the
tumour periphery fails to explain why early metastases,
especially in the case of mammary neoplasms, are local-
Number of lymphatics with and without VEGFR-3 expression in intratumoral (A, B) and extratumoral (C, D) fields in stage 0,  stage I and stage II malignant tumours Figure 3
Number of lymphatics with and without VEGFR-3 expression in intratumoral (A, B) and extratumoral (C, D) fields in stage 0, 
stage I and stage II malignant tumours.BMC Cancer 2007, 7:7 http://www.biomedcentral.com/1471-2407/7/7
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ized in the regional or collector lymph node, proving that
the neoplastic cells leaving the primary tumour spread via
the lymphatic pathway. In this respect, some chemical
mediators or ligand-receptor interactions (i.e. VEGF lig-
ands and VEGF receptors) might direct the neoplastic cells
to the lymphatic vessels.
In relation to tumour stage, VEGFR-3 expression in lym-
phatics was correlated with the histological stage of carci-
nomas, with a specific increase in VEGFR-3 expression in
the intratumoral stroma from St0 to StI and to StII.
VEGFR-3 expression is thought to be strictly related to the
formation of tumour metastasis and, consequently, to the
patient's prognosis. Human patients with the highest rel-
ative number of VEGFR-3 positive lymphatics and the
lowest relative number of blood vessels positive for the
same receptor had the highest probability of lymph node
metastases and therefore a negative prognosis [1]. The
presence of VEGFR-3 negative lymphatics is likely to indi-
cate a greater difficulty of neoplastic emboli entering neg-
ative rather than positive vessels for this receptor. Even if
results on haematic vessels are not reported in this paper,
many blood vessels were VEGFR-3 positive in intratu-
moral fields, demonstrating their recent formation. In
fact, the expression of this receptor by the endothelium of
tumoral blood vessels is well known, suggesting that
VEGFR-3 is involved in the angiogenesis of tumours and
in tumorigenesis [18,19,11]. The scant lymphangiogen-
esis inside the tumours may indicate that neoplastic cells
developing in a confined space create a mechanical stress
compressing the lymphatics or inhibiting their new for-
mation inside the tumour [20]. By contrast, blood vessel
angiogenesis would not be inhibited by major wall resist-
Cat Figure 4
Cat. Mammary gland. Strong cytoplasmic and light nuclear 
VEGF-C positivity in cells of solid carcinoma. 40X.
Table 1: VEGFR-3 expression in lymphatics of normal mammary gland, benign and malignant tumours.
Groups N° of lymphatics Spearman test
without VEGFR-3 (mean ± st. err; median) with VEGFR-3 (mean ± st. err; median)
Normal mammary gland avsb **
intramammary 2.43 ± 0.54; 2.16a 0.79 ± 0.18; 1.03cc vsd **
extramammary 4.03 ± 0.53; 4.55b 2.75 ± 0.41; 2.66de vsf NS
Benign tumours gvsh **
intratumoral 2.80 ± 0.66; 2.33e 0.93 ± 0.21; 1.05gi vsl **
extratumoral 4.20 ± 0.49; 3.76f 2.64 ± 0.36; 2.53hm vsn **
Malignant tumours avsevsi NS
intratumoral 3.76 ± 0.27; 3.50i 1.30 ± 0.18; 1.10m bvsfvsl *
extratumoral 4.55 ± 0.22; 4.44l 3.03 ± 0.15; 3.01nc vsgvsm NS
dvshvsn NS
Malignant tumours intratumoral
Stage 0 3.25 ± 0.44; 3.15o 0.73 ± 0.25; 0.70r
Stage I 4.07 ± 0.47; 3.70p 1.43 ± 0.42; 0.80so vspvsq NS
Stage II 5.06 ± 0.51; 4.58q 3.20 ± 0.34; 3.35tr vssvst *
Malignant tumours extratumoral uvsvvsw NS
Stage 0 3.52 ± 0.32; 3.37u 2.52 ± 0.25; 2.35xx vsyvsz NS
Stage I 5.06 ± 0.51; 4.58v 3.20 ± 0.34; 3.35y
Stage II 4.59 ± 0.17; 4.52w 3.12 ± 0.18; 3.15z
Descriptive statistical data of the number of lymphatics with or without VEGFR-3 expression in the compared groups. Spearman test: * = P < 0.05; 
** = P < 0.01; NS = non-significant.BMC Cancer 2007, 7:7 http://www.biomedcentral.com/1471-2407/7/7
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ance, but more likely by a local difference in the balance
of cytokines stimulating and inhibiting lymphangiogen-
esis.
Immunohistochemical VEGF-C positivity was observed
both in the cytoplasm and nucleus for the first time by
clone Z-CVC7 in the cat. Besides having a positive trophic
influence on vessel endothelium like other components
of the same family [21], anti-VEGF-C immunohistochem-
istry also stained epithelial cells. The data obtained com-
paring the expression of the epithelial component with
the number of positive vessels showed that the two are sig-
Table 2: VEGF-C expression in normal mammary gland, benign tumours, non-invasive and invasive malignant tumours.
Groups VEGF-C score index (mean ± st. err; median) Spearman Test
Normal mammary gland
intramammary 381.1 ± 437.4; 280.0aa vsb NS
extramammary 292.3 ± 336.6; 82.0b
Benign tumours
intratumoral 671.3 ± 309.5; 640.0cc vsd NS
extratumoral 530.1 ± 446.21; 630.0d
Non-invasive malignant tumours
intratumoral 667.0 ± 165.8; 820.0ee vsf NS
extratumoral 451.0 ± 127.1; 415.0f
Invasive malignant tumours
intratumoral 501.16 ± 83.5; 460.0gg vsh *
extratumoral 284.2 ± 70.6; 82.0h
Descriptive statistical data of VEGF-C score index in the compared groups. Spearman test: * = P < 0.05; NS = non-significant.
VEGF-C score index in normal mammary gland (A), benign tumours (B), non-invasive (C) and invasive malignant (D) tumours Figure 5
VEGF-C score index in normal mammary gland (A), benign tumours (B), non-invasive (C) and invasive malignant (D) tumours.BMC Cancer 2007, 7:7 http://www.biomedcentral.com/1471-2407/7/7
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nificantly associated. The factors inducing genic expres-
sion of VEGF-C in the endothelial wall, such as pro-
inflammatory cytokines (IL-1β and Tumour Necrosis Fac-
tor) [22,23], are also likely to influence epithelial cells.
Apart from the proportional relationship between the
increase in VEGF-C positivity of the epithelium and the
number of positive vessels, no relation was found
between the number of positive vessels and the diagnostic
group (comparison between normal mammary gland,
benign and malignant tumours), evaluation field (intratu-
moral/intramammary or extratumoral/extramammary)
and histological stage.
Based on the expression of VEGF-C of the epithelial com-
ponent, both normal gland and benign tumours pro-
duced similar results, for example regarding the
comparison between intratumoral (intramammary) and
extratumoral (extramammary) fields. The expression was
significantly higher in intratumoral than extratumoral
areas only in malignant tumours. The conditions stimu-
lating angiogenesis are likely to act in the intratumoral
areas due to mechanical stress [20] more than at the
periphery of the neoplasm where the vasculature is accen-
tuated. The same behaviour was observed in malignant
tumours grouped according to stage, for infiltrating (StI
and StII) but not for non-infiltrating carcinomas. The
enhanced intratumoral expression in infiltrating lesions
reflects their more pronounced angiogenetic need.
VEGF-C expression is not limited to the vascular endothe-
lium, but also regards the epithelium of normal and neo-
plastic gland. The inductive stimuli on the endothelium
may also induce ligand expression on the epithelium. This
expression is evident above all in infiltrating malignan-
cies, and especially in intratumoral hypoxic areas.
CD44 score index in extramammary/extratumoral fields of  NMG, BT and MT Figure 7
CD44 score index in extramammary/extratumoral fields of 
NMG, BT and MT. Cat Figure 6
Cat. Mammary gland. CD44 cytoplasmic positivity of carci-
noma infiltrating cells close to a lymph vessel. 40X.
Table 3: CD44 expression in normal mammary gland, benign and malignant tumours.
Groups CD44 score index (mean ± st. err; median) Spearman Test
Normal mammary gland
intramammary 720.8 ± 148.9; 1000aa vsb NS
extramammary 227.1 ± 130.1; 37b
Benign tumours
intratumoral 889.1 ± 110.9; 1000cc vsd **
extratumoral 379.9 ± 122.5; 181.1d
Malignant tumours
intratumoral 762.8 ± 65.8; 1000ee vsf **
extratumoral 438.1 ± 62.6; 320.5f
avscvse NS
bvsdvsf *
Descriptive statistical data of CD44 score index in the compared groups. Spearman test: * = P < 0.05; ** = P < 0.01; NS = non-significant.BMC Cancer 2007, 7:7 http://www.biomedcentral.com/1471-2407/7/7
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The results of VEGF-C were reproduced with CD44, with
enhancement of statistically significant differences, espe-
cially in benign and malignant tumours. Only stage I and
II infiltrating malignancies showed a different expression
in the intratumoral and extratumoral areas, being signifi-
cantly more pronounced in the intratumoral than extratu-
moral stroma. Different roles have been attributed to
CD44, such as cell adhesion, lymphocytic homing,
growth signals transmission and acquisition of invasive
malignant phenotype [24]. It is well-known that the deg-
radation of hyaluronic acid (a structural protein of the
extracellular matrix) plays an important role in tumour
invasion. CD44-mediated degradation of hyaluronic acid
around vessels allows tumour cells expressing the adhe-
sion molecule to enter the flow quickly and develop
metastases [25]. The higher values of CD44 expression in
the intratumoral hypoxic areas, especially in infiltrating
malignant tumours, are also likely to reflect such biologi-
cal functions in the neoplastic model.
The CD44-dependent endothelium-lymphocytes interac-
tion takes place only if lymphocytes are activated and the
endothelium stimulated by IL-2 [26]. This points out that
endothelial activation may be fundamental for entering
vessels. Following an activation signal, VEGFR-3 is
expressed by the vessel endothelium (VEGFR-3 is not
always expressed in all vessels). This may indicate neo-
plastic CD44 expressing cells are the means for entering
vessels thanks to an interaction with activated endothe-
lium. The inverse proportion between CD44 expression in
tumour cells and the number of lymphatics expressing
VEGFR-3 may be due to the role of CD44 in homophilic
cell aggregation. CD44-dependent cell aggregation has
been widely described [24]. Spontaneous homophilic
aggregation of many cell lines presenting CD44 depends
on the presence of this ligand that probably promotes the
adhesion of these cells [24]. In the pathogenesis of
tumoral progression, cell aggregation may protect meta-
static cells from the immunosurveillance mechanisms
facilitating their entrapment in target organs [24]. The
inverse relationship deriving from the results of the cur-
rent investigation is present in two different sites: intratu-
moral with high CD44 expression in the tumour cells
together with a low number of VEGFR-3 expressing lym-
phatics, and extratumoral showing the opposite. Extratu-
moral areas with scant CD44 (low efficient homotypic
adhesion), and the higher number of VEGRF-3 expressing
lymphatics (maximum preferential interaction of the neo-
plastic cell and the endothelium) would allow the neo-
plastic cells to enter the lymphatic pathway.
Conclusion
The tumour model employed in the present study pro-
vided no evidence of lymphangiogenesis, i.e. an increase
in the number of newly formed lymphatic vessels that
could have been proven by the increased expression of
VEGFR-3. In any case, it is likely that neoplastic cells reach
the regional lymph nodes following spread through the
pre-existing lymphatic network.
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